Febrile Neutropenia

01/01/2001 - "Febrile neutropenia was observed in two cases and resolved completely when antibiotics were introduced. "
03/01/2022 - "Safety and Efficacy of Antibiotic De-escalation and Discontinuation in High-Risk Hematological Patients With Febrile Neutropenia: A Single-Center Experience."
01/01/2022 - "The intervention protocol was associated with a significant reduction in time to initial antibiotics for ED patients with febrile neutropenia. "
07/01/2007 - "The management of febrile neutropenia has evolved significantly with the development of risk stratification and recognition of the efficacy of oral antibiotics in low-risk patients. "
06/01/2012 - "Outpatient and oral antibiotic management of low-risk febrile neutropenia are effective in children--a systematic review of prospective trials."

05/01/2006 - "For the G-CSF, the glycosylated form could still show itself more effective for the prevention of febrile neutropenias. "
08/01/2021 - "There has been no comprehensive analysis of the age-specific efficacy of G-CSF to prevent febrile neutropenia (FN). "
08/01/2019 - "Primary prophylaxis with granulocyte colony-stimulating factor significantly reduced the incidence of febrile neutropenia in this study. "
10/01/2013 - "The occurrence of severe or febrile neutropenia was within the range of that observed in previous studies of originator G-CSF. "
12/20/2010 - "Study inclusion criteria and presentation of results in a meta-analysis of granulocyte colony-stimulating factor for prevention of febrile neutropenia."

03/01/2023 - "This study aimed to show the trend of neutrophil counts and frequency of febrile neutropenia after changing pegfilgrastim from 3.6 mg to 1.8 mg. This case-series study was performed between April 2016 and December 2021 at Hyogo Prefectural Amagasaki General Medical Center. "
01/01/2023 - "Therefore, the study evaluated the prophylactic effectiveness of pegfilgrastim to reduce the incidence of febrile neutropenia associated with R-FC of patients with CLL. "
07/17/2019 - "This study revealed that the non-use of pegfilgrastim was an independent factor predictive of febrile neutropenia in multivariate analysis. "
11/01/2002 - "In addition, secondary endpoint results in both trials suggest an enhanced reduction in the overall incidence of febrile neutropenia with pegfilgrastim. "
12/01/2023 - "The primary endpoint compared the incidence of febrile neutropenia associated with pegfilgrastim administration timing. "

08/31/2023 - "Cefepime prophylaxis was associated with a significant reduction in BSIs, febrile neutropenia, and ICU admission among pediatric AML patients."
01/01/2017 - "The Dose-Dependent Efficacy of Cefepime in the Empiric Management of Febrile Neutropenia: A Systematic Review and Meta-Analysis."
03/01/2021 - "Our study identified no differences in clinical outcomes with cefepime 1 g q6h compared to the traditional FDA-approved 2 g q8h regimen for the treatment of febrile neutropenia."
04/01/2018 - "Larger clinical trials are necessary to determine if EI cefepime imparts a clinical benefit in the treatment of febrile neutropenia."
04/01/2018 - "The aim of this study was to determine the feasibility and clinical impact of administering cefepime by EI as treatment of febrile neutropenia. "

10/19/2021 - "Conclusions: Filgrastim was effective and safe in reducing febrile neutropenia and related complications, compared to placebo/no treatment. "
12/01/2017 - "The study results support noninferiority of filgrastim and filgrastim-sndz for prevention of febrile neutropenia requiring hospitalization. "
01/01/2009 - "In the two registrational studies of filgrastim, the cumulative incidence of febrile neutropenia (FN) was reduced by about 50% compared with placebo. "
12/01/2022 - "The incidence of febrile neutropenia was 21.6% in the filgrastim cohort and 15% in the filgrastim-aafi cohort (P = 0.179). "
10/19/2021 - "The risk ratio for febrile neutropenia was 0.58, a 42% reduction in favor of filgrastim. "

09/01/2015 - "The study results in Japanese patients with febrile neutropenia demonstrate that tazobactam/piperacillin treatment is efficacious and safe in adults. "
01/01/2019 - "PIPERACILLIN/TAZOBACTAM IN CONTINUOUS INFUSION VERSUS INTERMITTENT INFUSION IN CHILDREN WITH FEBRILE NEUTROPENIA."
09/01/2015 - "Efficacy and safety of tazobactam/piperacillin as an empirical treatment for the patients of adult and child with febrile neutropenia in Japan."
07/01/2013 - "Piperacillin-tazobactam as a cost effective monotherapy in febrile neutropenia."
11/01/2008 - "This prospective study investigated different sampling times in 30 patients receiving piperacillin/tazobactam for febrile neutropenia. "

07/01/2006 - "When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?"
07/01/2007 - "A relevant body of scientific evidence has been produced in the last 2 decades, through clinical trials addressing the efficacy of colony stimulating factors (CSFs) in the prevention and treatment of febrile neutropenia. "
01/01/2018 - "We evaluated trials included in a recent Cochrane review of granulocyte colony-stimulating factors for patients with febrile neutropenia. "
04/01/2004 - "Previous studies have used direct hospital costs to determine the threshold at which the cost of prophylactic use of colony-stimulating factor (CSF) is offset by savings from the lower risk of hospitalization for febrile neutropenia. "
05/01/1999 - "Economic analyses based on measures of resource utilization derived from randomized clinical trials have provided febrile neutropenia risk threshold estimates for the cost saving use of prophylactic colony-stimulating factor. "

06/01/2008 - "A pooled analysis comparing docetaxel administered weekly versus 3-weekly found similar survival rates between the schedules and a non-significant reduction in febrile neutropenia for the weekly regimen. "
11/01/2006 - "A pooled analysis comparing docetaxel administered weekly versus three-weekly found similar survival between the schedules and a non-significant reduction in febrile neutropenia for the weekly regimen. "
05/20/2023 - "Febrile neutropenia occurred in 11 patients treated with docetaxel 100 mg/m2, three of whom died, and in one patient treated with docetaxel 75 mg/m2. "
01/01/2020 - "Three-weekly docetaxel causes a high rate of febrile neutropenia, especially in the Asian population. "
12/01/2019 - "Febrile neutropenia occurred in 16% of the docetaxel patients. "

10/01/2020 - "Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interventional study."
08/01/2012 - "[A phase III study of the efficacy and safety of meropenem in patients with febrile neutropenia]."
01/01/2023 - "Evaluating the Use of Meropenem in Hematologic Patients with Febrile Neutropenia: A Retrospective Observational Single-Cohort Study."
11/01/2020 - "On the basis of these results, we suggest that meropenem should be reserved as a last resort for children with febrile neutropenia in countries with low antimicrobial resistance."
11/01/2020 - "Meropenem to Children With Febrile Neutropenia Induces Monoresistant Pseudomonas aeruginosa."

01/01/2019 - "To conduct a population pharmacokinetic analysis of continuous-infusion ceftazidime in a retrospective cohort of paediatric HSCT patients who were empirically treated for febrile neutropenia (FN) and who underwent therapeutic drug monitoring of ceftazidime steady-state plasma concentrations (Css) for optimization of drug exposure. "
11/01/2012 - "Institutional febrile neutropenia (FN) management protocols were changed following the finding of a high prevalence of ceftazidime-resistant Gram-negative bacteraemia (CR-GNB) among haematology patients with FN. "
01/01/2001 - "When considering our data in relation to known MIC values for common pathogens, ceftazidime administered intermittently every 6 h seems an appropriate regimen in patients with febrile neutropenia. "
05/01/1999 - "We assessed the clinical and economic impact of a new parenteral-toparenteral stepdown program involving ceftazidime for the treatment of febrile neutropenia. "
05/01/1999 - "Experience with ceftazidime parenteral-to-parenteral dosage stepdown in the empiric treatment of febrile neutropenia."

01/01/2018 - "Adjusting for the chemotherapy phase and ALL risk level, Enterococcaceae dominance (relative abundance ≥30%) predicted significantly greater risk of subsequent febrile neutropenia and diarrheal illness, whereas Streptococcaceae dominance predicted significantly greater risk of subsequent diarrheal illness. "
01/01/2016 - "Implementation of a computerized prescribing tool significantly increased the use of primary prophylaxis by treating physicians in patients receiving TC chemotherapy, which was associated with reduced incidence of febrile neutropenia. Further research efforts should focus on the incorporation and routine use of evidence-based practices using tools such as alerts and prompts, in order to optimize patient care and improve outcomes."
05/01/2008 - "The colony-stimulating have used effectively in a variety of clinical settings to prevent or treat febrile neutropenia and to assist patients receiving dose-intensive chemotherapy."
10/01/2011 - "Studies in patients receiving conventional chemotherapy have shown that chest radiographs do not appear to be helpful in the evaluation of asymptomatic patients with febrile neutropenia. "
01/01/2018 - "Febrile neutropenia (FN) is a frequent complication after chemotherapy, and its prevention could improve treatment density and degree of remission. "

01/01/2021 - "To determine if early discontinuation of antimicrobials in pediatric patients with low risk febrile neutropenia is as effective as continuing therapy before recovery of counts, in an outpatient setting. "
01/01/2007 - "Although the number of patients studied was limited, MCFG as a monotherapy seems to be effective and safe as an empirical therapy in patients with febrile neutropenia. "
10/01/2023 - "This study compared clinical outcomes in patients with acute myelogenous leukaemia (AML) who developed prolonged (≥4 days) febrile neutropenia (FN) and received either empirical or pre-emptive antimould prophylaxis in order to evaluate the need for routine empirical antifungal therapy. "
03/01/2023 - "Recent trials have shown early de-escalation of empiric antimicrobial therapy (EAT) in febrile neutropenia has led to less adverse effects with no difference in patient mortality. "
01/01/2018 - "Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study."

01/01/2019 - "The study's end-points are defined as dose reduction, hospitalization, and febrile neutropenia. "
04/01/2019 - "A Grade 4 adverse event(febrile neutropenia) occurred but the treatment was continued after a dose reduction to 80%. "
01/01/2019 - "Adding DEX to AI in STS patients leads to higher rates of bone marrow suppression in all blood components, as well as to more frequent events of febrile neutropenia and dose reductions."
01/01/2017 - "Indications for use were: prevent dose reduction/dose delay (81%, 207/256); treat FN or non-febrile neutropenia (NFN) (19%, 48/256). "
12/01/2014 - "At doses ≥ 40 mg BID, 7 patients had drug-related AEs that were serious but largely reversible/manageable by dose reduction and supportive care, including 3 with febrile neutropenia. "

05/01/2021 - "In the present study, we characterized the microbiomes of acute leukemia (AL) patients who achieved complete remission following remission induction chemotherapy (RIC) as outpatients, but who did not receive antimicrobials to treat or prevent febrile neutropenia. "
12/01/2018 - "Of 980 patients, 80.2% experienced febrile neutropenia (FN), 8.3% bacteremia/fungemia, and 10.3% pulmonary infection at least once during remission-induction chemotherapy. "
04/01/2013 - "During remission-induction chemotherapy, piperacillin-tazobactam therapy was started for febrile neutropenia. "
01/01/1996 - "Granulocyte-macrophage colony stimulating factor treatment of febrile neutropenia following remission induction chemotherapy for acute leukemia."
10/01/2008 - "A 33-year-old man was suffering from febrile neutropenia (FN) on day 15 after the start of remission-induction therapy for biphenotypic acute leukemia under gut decontamination with polymyxin B and nystatin. "

07/01/2018 - "Treatments were completed without febrile neutropenia or treatment delays. "
05/01/2012 - "There were two cases of febrile neutropenia (0.45%) and no treatment delays. "
11/01/2009 - "There were no episodes of febrile neutropenia, treatment delays or hospital admissions. "
10/01/2008 - "Feasibility was prospectively defined as febrile neutropenia in <10% of patients and </=1 treatment delay per cycles 1 to 3 and 4 to 6 in <20% of patients. "
11/01/2002 - "The purpose of this quality improvement project was to reduce treatment delays in patients with febrile neutropenia. "